165P - TIGIT inhibition in non-small cell lung cancer: Meta-analysis of clinical efficacy and biomarker correlation

Background

The role of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) as an immune checkpoint has garnered significant interest in oncology, particularly in the context of non-small cell lung cancer (NSCLC). TIGIT inhibition represents a promising therapeutic strategy, potentially enhancing anti-tumor immunity. This meta-analysis aims to evaluate the clinical efficacy of TIGIT inhibitors in NSCLC and to explore the correlation between TIGIT expression and relevant biomarkers.

Methods

A comprehensive literature search was conducted in databases such as PubMed, Scopus, and clinical trial registries up to June 2024. Studies were included if they reported clinical outcomes of TIGIT inhibitors in NSCLC patients. Data extraction focused on progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety profiles. Biomarker correlation analysis included TIGIT expression levels, PD-L1 status, and other immune-related markers. Statistical analysis involved pooled hazard ratios (HRs) for PFS and OS, and odds ratios (ORs) for ORR, with 95% confidence intervals (CIs).

Results

A total of 12 studies encompassing 1,750 patients were included. TIGIT inhibition showed a significant improvement in PFS (HR 0.73, 95% CI 0.61-0.87) and OS (HR 0.78, 95% CI 0.66-0.92) compared to standard treatments. The ORR was notably higher in the TIGIT inhibitor group (OR 1.45, 95% CI 1.21-1.73). Biomarker analysis revealed a positive correlation between high TIGIT expression and enhanced response rates. Additionally, patients with concurrent high PD-L1 expression demonstrated a synergistic benefit from TIGIT inhibition. The safety profile of TIGIT inhibitors was manageable, with no unexpected adverse events.

Conclusions

TIGIT inhibition offers a significant therapeutic benefit in NSCLC, improving survival outcomes and response rates. The correlation between TIGIT expression and clinical efficacy underscores the potential for biomarker-driven patient selection. These findings support further investigation and development of TIGIT inhibitors as a component of NSCLC treatment regimens.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.